In the framework the new ’Research Studio’ the Graz based scientists intend to further develop the agent Atglistatin for use on humans and to patent it.
The agent Atglistatin can reduce the level of fatty acid in the blood. Funded by the Austrian Research Promotion Agency, researchers at the University of Graz and TU Graz want to further develop the agent into a medicine to treat metabolic disorders. Worldwide, some 1.9 billion persons are overweight. 75 per cent of them suffer from a non-alcohol related fatty liver, and 400 million have type II diabetes. The illnesses are caused by a raised fatty acid level in the blood. The agent Atglistatin has been shown to reduce this, as a Graz research group of the University of Graz and TU Graz has recently found out. Researchers Rudolf Zechner and Robert Zimmermann, both from the University of Graz, and Rolf Breinbauer, from TU Graz, were able to produce Atglistatin synthetically.
UM DIESEN ARTIKEL ZU LESEN, ERSTELLEN SIE IHR KONTO
Und verlängern Sie Ihre Lektüre, kostenlos und unverbindlich.
